Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study

Purpose Apatinib, a new tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, has shown promising efficacy against several solid cancers, but evidence of its efficacy against relapsed and refractory nasopharyngeal carcinoma is limited. We investigated the efficacy and sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ling, Kong, Fei, Zhang, Lei, Li, Xin, Fu, Xiaorui, Wang, Xinhua, Wu, Jingjing, Zhang, Fangwen, Ren, Liangliang, Zhang, Mingzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Phase II Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575486/
https://www.ncbi.nlm.nih.gov/pubmed/32363427
http://dx.doi.org/10.1007/s10637-020-00925-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575486/
https://www.ncbi.nlm.nih.gov/pubmed/32363427
http://dx.doi.org/10.1007/s10637-020-00925-2

Ejemplares similares